AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin
Avita Medical Price Target Cut 9% to A$2.75/Share by Wilsons
Avita Medical Price Target Cut 9% to A$2.75/Share by Wilsons
AVITA Downgraded by Piper Sandler Over Sales Outlook
Piper Sandler: The AVITA Medical (RCEL.US) rating was lowered from an increase in holdings to a neutral rating, and the target price was adjusted from $21.00 to $9.00.
Piper Sandler: The AVITA Medical (RCEL.US) rating was lowered from an increase in holdings to a neutral rating, and the target price was adjusted from $21.00 to $9.00.
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Inotiv (NOTV) and Hims & Hers Health (HIMS)
Bank of America Securities Remains a Buy on Avita Medical (RCEL)
Avita Medical Price Target Cut to $21.00/Share From $22.00 by Cantor Fitzgerald
Avita Medical Price Target Cut to $21.00/Share From $22.00 by Cantor Fitzgerald
Avita Medical Is Maintained at Overweight by Cantor Fitzgerald
Avita Medical Is Maintained at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Maintains Overweight on AVITA Medical, Lowers Price Target to $21
Cantor Fitzgerald analyst Ross Osborn maintains AVITA Medical (NASDAQ:RCEL) with a Overweight and lowers the price target from $22 to $21.
AVITA Medical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 161.52% Cantor Fitzgerald $22 → $21 Maintains Overweight 04/11/2024 — BTIG Downgrades Buy → Ne
Q1 2024 AVITA Medical Inc Earnings Call
Piper Sandler Reaffirms Their Hold Rating on Avita Medical (RCEL)
Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target Is $9
Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target is $9.
Steady Performance and Promising Outlook: A Buy Rating for Avita Medical
AVITA Medical, Inc. (RCEL) Q1 2024 Earnings Call Transcript
AVITA Medical, Inc. (RCEL) Q1 2024 Earnings Call Transcript
AVITA Medical Inc (AVHHL) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges ...
Avita Medical Widens Q1 Loss as Sales, Marketing Expense Jumps; Shares Up 10%
Avita Medical (ASX:AVH) widened first-quarter net loss to $18.7 million, or $0.73 per share, from $9.2 million, or $0.37 per share, in the fourth quarter of 2023. Revenue rose on-quarter to $11.1 mill
10-Q: Quarterly report
AVITA Medical Sees Q2 Commercial Revenue $14.3M-$15.3M; FY24 Commercial Revenue Expected To Be In The Lower End Of Previous Guidance Of $78.5M-$84.5M
Financial GuidanceCommercial revenue for the second quarter 2024 is expected to be in the range of $14.3 to $15.3 millionCommercial revenue for the full-year 2024 is expected to be in the lower end of
1Q Loss/Shr 73c >AVH.AX.AU
1Q Loss/Shr 73c >AVH.AX.AU
No Data